Archives of Pharmacal Research

  • 제27권10호
  • /
  • Pages.997-1000
  • /
  • 2004
  • /
  • 0253-6269(pISSN)
  • /
  • 1976-3786(eISSN)
대한약학회 (The Pharmaceutical Society of Korea)
권호 표지

Synthesis and In Vitro Cytotoxicity of 1,3-Dioxoindan-2-Carboxylic Acid Arylamides

  • 발행 : 2004.01.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

A series of 1,3-dioxoindan-2-carboxylic acid arylamides were synthesized and evaluated for in vitro cytotoxicity against four human cancer cell lines (HOP62, SK-OV-3, MD-MB-468 and T- 47D). The most active was compound 3e (1.2 ${\mu}M$ against SK-OV-3 cell line) bearing a 4- methyl substituent.

키워드

참고문헌

  1. Aoyagi, Y., Kobunai, T., Utsugi, T., Oh-hara, T., and Yamada, Y., In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II. Jpn. J. Cancer Res., 90, 578-587, (1999) and references cited therein https://doi.org/10.1111/j.1349-7006.1999.tb00786.x
  2. Atwell, G. J., Rewcastle, G. W., Baguley, B. C., and Denny, W. A., Potential antitumor agents. 50. In vivo solid tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J. Med. Chem., 30, 664-669(1987). https://doi.org/10.1021/jm00387a014
  3. Baguley, B. C., Zhuang, L., and Marshall, E. M., Experimental solid tumor activity of N-[2-(dimethylamino)-ethyl] acridine-4-carboxamide. Cancer Chemather. Pharmacal., 36, 244-248 (1995). https://doi.org/10.1007/BF00685854
  4. Bonner, J. A. and Kozelsky, T. F., The significance of the sequence of administration of topotecan and etoposide. Cancer Chemather. Pharmacal., 39, 109-112 (1996) https://doi.org/10.1007/s002800050545
  5. Cortes, F. and Pinero, J., Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells. Cancer Chemather. Pharmacal., 34, 411-415(1994) https://doi.org/10.1007/BF00685566
  6. Dittrich, C., Coudert, B., Paz-Ares, L., Caponigro, F., Salzberg, M., Gamucci,T., Paoletti, X., Hermans,C., and Lacombe, D., Fumoleau P. and on behalf of the European Organization for Research and Treatment of CancerEarly Clinical Studies Group/New Drug Development Programme(EORTC-ECSG/ NDDP), Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer. European J. Cancer, 39,330-334 (2003) https://doi.org/10.1016/S0959-8049(02)00559-2
  7. Kaslow, C. E. and Sommer, N. B., SubstitutedLepidines. J. Am. Chem. Soc., 68, 644-646(1946) https://doi.org/10.1021/ja01208a035
  8. Lee, H., Lee, J., Hong, S-. S., Yang, S-. I., Jung, S.-H., Jahng, Y., and Cho, J., Synthesis and in vitro cytotoxicity of 2-alkylaminosubstituted quinoline derivatives. Arch. Pharm. Res., 23, 450-454 (2000) https://doi.org/10.1007/BF02976570
  9. Lee, H., Lee, J., and Yang, S-I., Synthesis and in vitro cytotoxicity of 4-alkyl- or 4-arylaminosubstituted cyclopenta [c]quinoline derivatives. Arch. Pharm. Res., 24, 385-389 (2001) https://doi.org/10.1007/BF02975180
  10. Minderman, H., Wrzosek, C., Cao, S. S., Utsugi,T., Kobunai, T., Yamada, Y, and Rustum, Y. M., Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells. Cancer Chemather. Pharmacal., 45, 78-84 (2000)and references cited therein. https://doi.org/10.1007/PL00006747
  11. Potts, K. T., Bhattachaarjee, D., and Walsh E. B., Cycloaddition routes to azaanthraquinone derivatives. 1. use of azadienophiles. J. Org. Chem., 51, 2011-2021 (1986) https://doi.org/10.1021/jo00361a014
  12. Skehan, P., Storeng, R., Scudiero, D, Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenny, S., and Boyd, M. R., New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82, 1107-1112 (1990) https://doi.org/10.1093/jnci/82.13.1107